A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

The purpose of this Phase 3 study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

To Learn More Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com or call 855-907-3286 or email Clinical.Trials@bms.com. First line of the email must contain the NCT number and the number of the trial site.

ClinicalTrials.gov identifier (NCT number): NCT05617677

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up